Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Imke H. Bartelink, Chris Dickhoff, Johannes M.A. Daniels, Peter M. van de Ven, Joris Veltman, Sayed M.S. Hashemi, Idris Bahce, Suresh Senan, Teodora Radonic, Juan J. Garcia-Vallejo, Tanja D. de Gruijl, Marieke L. Fransen, Famke L. Schneiders, David J. Heineman, Lilian J. Meijboom, Daniela E. Oprea-Lager
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer, 20(1):764. BioMed Central
Dickhoff, C, Senan, S, Schneiders, F L, Veltman, J, Hashemi, S, Daniels, J M A, Fransen, M, Heineman, D J, Radonic, T, van de Ven, P M, Bartelink, I H, Meijboom, L J, Garcia-Vallejo, J J, Oprea-Lager, D E, de Gruijl, T D & Bahce, I 2020, ' Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial ', BMC Cancer, vol. 20, no. 1, 764 . https://doi.org/10.1186/s12885-020-07263-9
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer, 20(1):764. BioMed Central
Dickhoff, C, Senan, S, Schneiders, F L, Veltman, J, Hashemi, S, Daniels, J M A, Fransen, M, Heineman, D J, Radonic, T, van de Ven, P M, Bartelink, I H, Meijboom, L J, Garcia-Vallejo, J J, Oprea-Lager, D E, de Gruijl, T D & Bahce, I 2020, ' Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial ', BMC Cancer, vol. 20, no. 1, 764 . https://doi.org/10.1186/s12885-020-07263-9
BackgroundThe likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens